鞘脂在肝脏疾病中的作用研究进展

www.yongyao.net　　2009-9-2 17:39:36　　来源：　　责任编辑：

分享到：

5 参考文献
[1] Lagarde M, Geloen A, Record M, et al. Lipidomics is emerging[J ]. Biochim Biophys Acta, 2003, 1634:61.
[2] Hannun Y A, Bell R M. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation[J ]. Science, 1989,243:500- 507.
[3] Morales A, Lee H, Felix M, et al. Sphingolipids and cell death[J ].Apoptos is , 2007, 12:923- 939.
[4] Ogretmen B, Hannun Y A. Biologically active sphingolipids in cancer pathogenes is and treat - ment [J ] . Nat Rev Cancer2004,4:604- 616.
[5] Fahy E, Subramaniam S, Brown H A, et al. A comprehens iveclas s ification sys tem for lipids [J ]. J Lipid Res , 2005, 46:839- 861.
[6] Ohanian J , Ohanian V. Sphingolipids in mammalian cell s ignaling[J ]. CellMol Life Sci, 2001, 58:2053- 2068.
[7] Cuvillier O, Pirianov G, Kleuser B, et al. Suppres s ion of ceramide mediated programmed cell death by sphingos ine- 1- phosphate[J ]. Nature, 1996, 381:800- 803.
[8] Raquel P, Albert M, Olga C, et al. Ganglios ide GD3 sens itizes human hepato - ma cells to cancer therapy [J ] . J Bio Chem,2002, 277:49870- 49876.
[9] Llacuna L, Mari M, Garcia- Ruiz C, et al. Critical role of acidic sphingomyelinase in murine hepatic ischemia- reperfus ion injury[J ]. Hepatology, 2006, 44:561- 572.
[10] Bradham C A, Stachlewitz R F, Gao W S, et al. Reperfus ionafter liver transplantation in rats differentially activates the mitogen- activated protein kinases [J ] . Hepatology, 1997, 25:
1128- 1135.
[11] Liu Z G. Adding facets to TNF s ignaling, The JNK angle [J ]. MolCell, 2003, 12:795- 796.
[12] Umehara T, Sudoh M, Yasui F, et al. Serine palmitoyl trans ferase inhibitor suppres ses HCV replication in a mouse model[J ].Biochem Biophys Res Commun, 2006, 346:67- 73.
[13] Sakamoto H, Okamoto K, Aoki M, et al. Hos t sphingolipid biosynthes is as a target for hepatis C virus therapy [J ] . NatChem Biol,2005,1:333- 337.
[14] Kok J W, Sietsma H.Sphingolipid metabolism enzymes astargets for anti- cancer therapy[J ]. Curr Drug Targets , 2004, 5:375- 382.
[15] Kandyba A G, Kobliakov V A, Somova O G, et al. Change in contents of biologically active sphingolipids modulating cellgrowth and survival in hepatoma 27 compared to rat liver [J ] .Biochemis try (Mosc), 2004, 69:497- 500.
[16] Sietsma H, Veldman R J , Kok J W, et al. The involvement of sphingolipids in multidrug res is ta nce [J ] . J Membr Biol, 2001,181:153- 162.
[17] Morales A, Paris R, Villanueva A, et al. Pharmacological inhibition or small interfering RNA targeting acid ceramidasesens itizes hepatoma cells to chemotherapy and reduces tumorgrowth
in vivo[J ]. Oncogene, 2007, 26:905- 916.
[18] Maurer B J , Melton L, Billups C, et al. Synergis tic cytotoxicity in solid tumor cell lines between N- (4- hydroxyphenyl)retinamide and modulators of ceramide.Metabolism[J ]. J Natl Cancer Ins t,2000, 92:1897- 1909.
[19] Visentin B, Vekich J A, Sibbald B J , et al. Validation of an antisphingosine- 1- phosphate antibody as a potential therapeuticin reducing growth, invas ion,and angiogenes is in multiple tumor
lineages [J ]. Cancer Cell, 2006, 9:225- 238.
[20] Pyne S, Pyne N. Sphingos ine- 1- phosphate s ignalling via the endothelial differentiation gene family of G- proteincoupled receptors[J ]. Pharmacol Ther, 2000, 88:115- 131.
[21] Goetzl E J , Wang W, McGiffert C, et al. Sphingos ine-1- phosphate and its G protein- coupled receptors cons titute amultifunctional immunoregulatory sys tem [J ]. J Cell Biochem,2004, 92: 1104- 1114.
[22] Mandala S, Hajdu R, Bergs trom J , et al. Alteration of lymphocyte trafficking by phingos ine - 1 - phosphate receptor agonis ts[J ]. Science, 2002, 296:346- 349.
[23] Wang ME, Tejpal N, Qu X, et al. Immunosuppres s ive effects of FTY720 alone or in Combin- ation with cyclosporine and/ors irolimus[J ]. Transplantation, 1998, 65:899- 905.